[1]Zhao GS, Zhang Q, Quan ZX. Mid-term efficacy and safety of cervical disc arthroplasty versus fusion in cervical spondylosis: A systematic review and meta-analysis[J]. Biomed Rep, 2017, 6 (2):159-166.
[2]Alli S, Anderson I, Khan S. Cervical spondylotic myelopathy[J]. Br J Hosp Med (Lond), 2017, 78 (3): C34-C37.
[3]赵树军, 范里, 王博学, 等. 壮骨益髓颗粒治疗脊髓型颈椎病[J]. 长春中医药大学学报, 2015, 31(1): 143-145.
[4]Nagashima H, Morio Y, Yamane K, et al. Tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in the cerebrospinal fluid of patients with cervical myelopathy and lumbar radiculopathy[J]. Eur Spine J, 2009,18 (12):1946-1950.
[5]施杞, 郝永强, 彭宝淦, 等. 动静力平衡失调与颈椎病—颈椎病动物模型的实验研究[J]. 上海中医药大学学报, 1999, 13(1): 52-56.
[6]宋沛松, 孔抗美, 齐伟力, 等. 肌力失衡与后柱失稳大鼠颈椎病模型的研究[J]. 汕头大学医学院学报, 2004, 17(2): 70-72.
[7]李沁彤, 耿昶, 占文. 颈椎病与中医辨证关系的探讨[J]. 辽宁中医杂志, 2010, 37(1): 116-117.
[8]Karateev AE, Erdes ShF. Use of nonsteroidal anti-inflammatory drugs in case of ankylosing spondylitis: long and persistently[J]. Ter Arkh, 2014, 86(11): 123-127.
[9]Puvanesarajah V, Jain A, Shimer AL, et al. Complications and mortality following one to two-level anterior cervical fusion for cervical spondylosis in patients above 80 years of age[J]. Spine (Phila Pa 1976), 2017, 42(9): E509-E514.
[10]赵聚凯, 陈庆平, 高梁斌, 等. 活血化瘀对颈椎病动物模型局部血流量与组织的影响[J].浙江中西医结合杂志, 2002, 12(11): 683-684.
[11]Okada S, Chang C, Chang G, et al. Venous hypertensive myelopathy associated with cervical spondylosis[J]. Spine J, 2016, 16(11):e751-e754.
[12]Okoro T, Tafazal SI, Longworth S, et al. Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica[J]. J Spinal Disord Tech, 2010, 23 (1):74-77.
[13]Burke JG, Watson RW, MeCormack D, et al. Spontaneous Production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc[J]. Spine, 2002, 27 (13):1402-1407. |